Highlights in Renal Cell Carcinoma From ASCO 2021

Eric Jonasch, MD


June 25, 2021

Dr Eric Jonasch, of the University of Texas MD Anderson Cancer Center, highlights studies in renal cell carcinoma (RCC) presented at the ASCO 2021 Annual Meeting.

Dr Jonasch first reports on the late-breaking KEYNOTE-564 study, the first positive phase 3 study of adjuvant immunotherapy in RCC. Pembrolizumab may offer a potential new standard of care, demonstrating a 32% reduction in the risk for recurrence or death compared with placebo.

Next, he comments on the health-related quality-of-life update from the CLEAR trial, which seems to further support lenvatinib in combination with pembrolizumab as first-line therapy for patients with advanced RCC.

Finally, Dr Jonasch reports exciting results for hard-to-treat cases, including treatment for variant histology and management of patients with brain metastases, who are usually excluded from RCC trials.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.